Amisulpride is an atypical antipsychotic drug belonging to the substituted benzamide class, mainly used in the treatment of schizophrenia and other psychotic disorders. It works by selectively blocking dopamine D₂ and D₃ receptors, particularly in the limbic system, which helps control positive symptoms such as hallucinations and delusions, as well as negative symptoms like social withdrawal and lack of motivation. The drug was developed in France by Sanofi-Synthélabo in the 1970s and was introduced into clinical use during the late 1980s and early 1990s in Europe. It became well known for its effectiveness in managing negative symptoms of schizophrenia, where many older antipsychotics were less effective. Over the years, amisulpride has been widely used in several countries and has also been approved in some regions for additional uses, including dysthymia and, at low doses, for the prevention of postoperative nausea and vomiting.
Image
